Randy W. Schekman
Nobel laureate, the 2013 Nobel Prize in Physiology or Medicine
Professor of Molecular and Cell Biology, University of California, Berkeley
Randy Wayne Schekman is a Nobel Prize-winning professor in Cell Biology at the University of California - Berkeley. He was the former editor-in-chief of Proceedings at the National Academy of Sciences. Dr. Schekman was elected to that prestigious academy in 1992. In 2011 Dr. Schekman was chosen as the editor of eLife, a new, high profile, open access journal published by the Howard Hughes Medical Institute, the Max Planck Society and the Wellcome Trust.
Dr. Schekman shared the 2013 Nobel Prize for Physiology or Medicine with James Rothman and Thomas C. Sudhof for their ground breaking work on cell membrane vesicle trafficking.
Kevin Chen
Managing Partner, Biotrack Capital
Kevin (Penghui) Chen is Managing Partner of Biotrack Capital. Prior to this, he was partner at Sequoia Capital , responsible for healthcare investment. Before Sequoia Capital,  Kevin (Penghui) Chen served as head and managing director of Everbright Healthcare Fund since December 2011. At Everbright, Mr Chen led the fund raising operation, and investment efforts.  
Kevin has led investment in many leading healthcare companies in China such as BGI, Amcare, Betta Pharmaceuticals Inc, JIDA Pharmaceuticals Inc, Yuwell Medical, Zai Lab, Medtrum Medical, STP, Bai Yang Pharmaceuticals, Forerunner Medical, Guahao, etc.  Before Everbright, he served as President of ShangPharma, a leading China CRO company in 2011. Kevin was the COO & CFO of ShangPharma between 2008 and 2010 and took the company public at NYSE in 2010. 
Prior to ShangPharma, Kevin was a vice president at CITIC Capital, responsible for healthcare and consumer industry. Before CITIC Capital, Kevin took executive positions at BD & Corporate Investment at fortune 500 multinational companies. Kevin also worked as research scientist at Ligand Pharmaceuticals (Nasdaq: LGND) in San Diego, California. 
Mr. Chen holds a bachelor degree in chemistry from Nanjing University, master degree in medicinal chemistry from Tulane University and an MBA from Kellogg School of Management, Northwestern University.
Ted Driscoll
Prior to joining Decheng, Dr. Driscoll was a Partner at Claremont Creek Ventures leading its efforts in Digital Healthcare and Diagnostics. He led the first investments in Natera (IPOed in 2015), AssureX Health (acquired by Myriad Genetics for $410M) and GeneWeave Biosciences (acquired by Roche for $425M). Prior to entering venture capital, he was an early leader or founder of five startups. During his startup experience he was the inventor of over 50 patents.
He graduated from Stanford with a Ph.D. in Digital Imaging, and previously received a Masters in Computer Graphics from Harvard, and a BA from the University of Pennsylvania.
DeCheng Capital: Decheng Capital is a leading venture capital firm that provides capital to early and growth stage life science companies in China. They are a team of investment professionals with complementary expertise, a long history of working together and a shared dedication to building highly successful companies that span the full spectrum of the life sciences industry.
Julie Papanek Grant
Partner, Canaan
As Partner of Canaan, Julie brings deep operational experience to her biopharma and digital health investments, having previously worked at Genentech across development and commercial divisions. Julie serves on the board of the Biden Cancer Initiative and co-chairs Planned Parenthood NorCal’s IT Advisory Board. In 2017, she was named one of Silicon Valley Business Times’ 40 Under 40. Julie holds an M.B.A. from Stanford, an MPhil. in BioScience Enterprise from Cambridge and a B.S. in Molecular Biophysics and Biochemistry from Yale.
Canaan: Canaan is an early-stage venture capital firm that invests in visionaries with transformative ideas. While we love speedy success, we’re acutely aware that greatness comes in many forms and at different times. That’s why we’re not afraid to break the mold to bring something spectacular to life.
Nanxing He
Executive Partner, Sangel Ventures
Patrick Heron
Managing General Partner, Frazier Healthcare Partners
Patrick is a Managing General Partner of Frazier’s Life Sciences team. He joined the firm in 1999 and opened Frazier’s Menlo Park office in 2003. Throughout his 12 years as a General Partner, Patrick has led or co-led investments across nearly 20 companies.
Patrick has successfully partnered with entrepreneurs across a range of company types and stages, from early-stage anti-infectives companies to >$100M commercial-stage dermatology companies. Patrick has also been active in company formation around both early- and later-stage assets. He has led and served as director for many successful Frazier Life Sciences investments, including Tobira Therapeutics (acquired by Allergan), Marcadia (acquired by Roche), Calixa (acquired by Cubist), Cerexa (acquired by Forest), PreCision Dermatology (acquired by Valeant), MedPointe (acquired by Meda), and Collegium (NASDAQ: COLL). He currently serves on the boards of Imago BioSciences, Iterum Therapeutics, Silvergate Pharmaceuticals, SutroVax and Zavante Therapeutics.
Prior to joining Frazier, Patrick helped develop McKinsey & Company's West Coast biotechnology consulting practice, where he led projects involving mergers and acquisitions, product launches, sales force optimization, corporate partnering, and research prioritization.
Patrick received his M.B.A. from Harvard Business School. He also holds a B.A. from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and Morehead Scholar.
Hongjie Hu
Investment Director, Temasek
James Huang
Managing Partner, KPCB China
James Huang joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. James has made more than 15 investments in China since 2007.
Before coming to KPCB China, James was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo, James led numerous investments in China. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson). James is Chairman of Board at Kindstar Global, JHL Biotech and Director at GenScript, ChiralQuest, Zenesis, CVie Therapeutics, EntreMed, XW Laboratory and Omni Pharmaceuticals.
James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley. He was born in Taipei, Taiwan.
Alexis Ji
Partner, Illumina Ventures
Alexis Ji brings 12 years of experience in research and venture investment in the genomics and pharmaceutical industries. At Illumina Ventures, Alexis focuses on investing in early-stage genomics technology platforms and applications in life science tools, diagnostics, therapeutics, and digital health.
Prior to Illumina Ventures, Alexis was a principal at WuXi Apptec Corporate Venture Fund and then WuXi Healthcare Ventures, a U.S.-China cross-border life science venture capital firm. Alexis was instrumental in investments in Twist Bioscience, 23andme, Juno Therapeutics, Syros Pharmaceuticals, Unity Biotechnology, Vivace Therapeutics, Medeor Therapeutics, Ideaya Therapeutics, and Lumo Bodytech. Before joining WuXi, Alexis was a venture investment consultant at ARCH Venture Partners.
Illumina Ventures: An independently managed venture fund in a strategic partnership with Illumina. Illumina provides the majority of our capital and access to the expertise and vision of the world's leading genomics solutions provider.
Clarence Kho
Managing Director, Converge Minds
Clarence Kho has more than 25 years of experiences in the petrochemical industry across China, Asia, and the United States. He has strong track record in strategy formulation and implementation, sales and marketing, safety and operation management, project investment, Joint Venture management and M&A. While VP of Greater China Acetyls, he developed business vision and strategies to meet challenges of the dynamic environment and took the business to the next level by leading the 1.2 million ton ($500 million revenue) Acetic Acid (AA) business to achieve performance goals on growth, P&L, operation and organizational development. He also was VP of Sales, Marketing, Supply and Logistics, President of BP Zhuhai (BPZ) PTA Plant, and Asia Venture Coordination Manager in BP.
Mr. Kho served on the Board of Directors of CAPCO and Formosa BP Acetyls in Taiwan, YARACO, Byaco and BP Zhuhai in China, and was VP of PT Ami in Indonesia.
Mr. Kho holds an MBA from the University of Hull in England and a BS in Chemical Engineering from De La Salle University in the Philippines.
Yanhong Lin
Founder and Managing Partner, CTIC Capital
Yanhong Lin is the Founder and Managing Partner at CTIC Capital. CTIC Capital provides investment banking services to companies in the field of Healthcare, IT and Energy. Yanhong and her team have successfully raised funding for US medical device companies and high tech companies.
Yanhong has close ties to venture capital firms in both Silicon Valley and Boston. She has established herself as a trusted advisor to VCs and entrepreneurs. Her clients are portfolio companies of top US VCs like General Catalyst, Khosla Venture, Prospect Venture, NEA and Third Rock. Her Chinese clients include top public traded Chinese companies.
Yanhong Lin has over 20 years of work experiences with Fortune 100 companies in the high tech and energy industries (Sun Microsystems, HP/Agilent and Amoco (now BP). Prior to founding CTIC Capital, she led the Corporate Financial Planning and Analysis team at Sun Microsystems (a $12 billion revenue company) with responsibilities of company’s forecast and P&L analysis.
Yanhong is a committee member of MIT Club of Northern California Energy and Environment, which was awarded the 2016 MIT Great Dome Award (is the highest honor that the MIT Alumni Association bestows upon any of its organizations). She is also an advisor to the Stanford Precourt Institute for Energy and successfully helped Chinese companies get engaged with Stanford. Yanhong was also served as Chair of the VC Taskforce China SIG (Special Interest Group).
Yanhong was born in Shanghai and grew up in Nanjing. She received BA from Western Illinois University in 1991 and her MBA from University of Illinois at Champaign-Urbana in 1993. She lives with her husband and two Children in Palo Alto, California. She enjoys skiing, traveling and spinning/biking.
Hongbo Lu
Partner, Lily Asia Ventures
Dr. Hongbo Lu is a partner at Lilly Asia Ventures, a healthcare-focused investment firm with over USD$1.2 billion AUM. Previously, Dr. Lu was with OrbiMed Advisors, serving as its Managing Director in Asia, responsible for over $500m public equity investment portfolio in emerging markets, as well as led a few private equity investments and served as board of directors of private and public companies. 
Dr. Lu has over 15 years of investment and operational experience in healthcare industry, including her tenures at OrbiMed, Piper Jaffray & Co. and life science start-up Zyomyx. Dr. Lu received a Ph.D. in Bio Engineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and graduated with honor from Tsinghua University in China.
Xiaobo Lu
Partner, Sequoia Capital China
Before joining Sequoia Capital China, Mr Lu served as a healthcare partner of Shenzhen Co-Win Venture Capital Investment Limited, focusing on healthcare investment. During his seven years in Co-Win Venture Capital, he led over 30 healthcare investment, including: BGI (SZSE:300676); Betta Pharmaceuticals (SZSE:300558); Jingfeng Pharmaceuticals (SZSE:000908); Konruns Pharmaceuticals (submitted listing applications); Chipscreen; Innovent; Zhongankang (acquisition and take private); etc. Before Co-Win Venture Capital, Mr.Lu had 15 years of experience in pharmaceuticals sales and marketing. He worked in China Resource Sanjiu for almost ten years with rich experience and knowledge in Chinese pharmaceutical market and identifying healthcare investment opportunities.
Mr. Lu obtained a bachelor’s degree in biochemistry engineering from Zhejiang University and an MBA degree from Tsinghua University.
Xiangyu Ouyang
Managing Director, Legend Capital
Mr. Ouyang Xiangyu has built up the team and led the investments in healthcare sector in the firm. He has rich experience in company strategies, corporate governance, business operation, and venture investing. Since 2010, healthcare deals led by Mr.Ouyang include Wuhan Asia Heart Hospital, BONOVO, Reach Surgical, ET Healthcare, Access Medical, Beijing Berry Genomics, U-Topstar, Jenavalve, Kailian Meidcal, KangDa Medical, DL Biotech and POCTech.
Mr. Ouyang graduated from Wuhan University in 1986 with a bachelor’s degree. In 1992, he received a master’s degree in Electronic Engineering from Tsinghua University, and in 2009, he received his EMBA degree from the Cheung Kong Graduate School of Business.
Legend Capital: Legend Capital is one of leading Venture Capital investment, subsidiary under the Lenovo holdings company.
Amy Schulman
Entrepreneur Partner, Polaris Partners
Amy Schulman is an Entrepreneur Partner focused on funding and founding companies in the healthcare sector. Upon joining Polaris in 2015, assumed the role of Chief Executive Officer of Arsia Therapeutics, a Polaris-backed company acquired by Eagle Pharmaceuticals (NASDAQ: EGRX) in November 2016.In July 2015, Amy co-founded Lyndra, where she is CEO and in 2017 became CEO of Olivo Laboratories, both Polaris-backed companies. Also on behalf of Polaris, she serves as the Executive Chair of SQZ Biotech and Suono Bio and is director of Alnylam Pharmaceuticals (NASDAQ: ALNY) and Ironwood Pharmaceuticals (NASDAQ: IRWD). In addition, she serves as a director of Blue Buffalo (NASDAQ: BUFF) and the Whitehead Institute.
Prior to these roles, Amy was responsible for leading Pfizer Inc.’s (NASDAQ: PFE) $4 billion Consumer Healthcare business, which operates in 90 countries and includes well-known brands such as Advil, Centrum, and Chapstick. She also served concurrently as Executive Vice President and General Counsel of Pfizer Inc. Previously at Pfizer, Amy was SVP, President & General Manager of the infant formula and nutrition business where she was instrumental in the unit’s sale to Nestle for $11.85 billion in 2012. Before joining Pfizer, Amy was a Partner at DLA Piper, where she was a member of the Board and Executive Policy Committees, and built and led the international law firm’s mass tort and class-action practice.
Amy is the recipient of numerous awards and distinctions including: Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, Fortune Magazine’s 2013 50 Most Powerful Women in Business, The American Lawyer’s 2013 Top 50 Innovators, and The National Law Journal’s 2013 100 Most Influential Lawyers in America.Amy is a member of Harvard Business School’s Faculty where she serves as a Senior Lecturer and teaches legal and corporate accountability. A Phi Beta Kappa graduate of Wesleyan University, Amy earned her J.D. from Yale Law School in 1989.
Christopher Shen
Managing Partner, Qiming Venture
Prior to joining Qiming, Dr. Shen was a Managing Director and head of U.S. healthcare investing at Vertex Ventures Healthcare. Dr. Shen specializes in investments in biopharmaceutical and medical device companies. Previously, Dr. Shen worked at Essex Woodlands Health Ventures, a healthcare-focused venture capital and private equity firm. Prior to joining EWHV, he worked at New Enterprise Associates, one of the largest, diversified venture capital firms. Previously, Dr. Shen held the position of Senior Design Engineer at Guidant Corporation's Neurovascular Venture, an internal start-up, where he invented and commercialized a minimally-invasive therapy for the treatment of acute ischemic stroke. Dr. Shen also worked in Japan as a Design Engineer for Pfizer, Inc.’s Strategic Innovation Group, an internal medical technology incubator.
Dr. Shen is the U.S. Executive Director of the Singapore Stanford Biodesign Program and a Consulting Associate Professor of Medicine at Stanford University, focusing on medical technology innovation. He has nine patents issued and several pending in the fields of interventional neuroradiology and interventional cardiology.
Dr. Shen received his Doctor of Medicine from the Stanford School of Medicine, his Master of Business Administration from Stanford Graduate School of Business, and a Master of Biomechanical Engineering from the Stanford School of Engineering. He received his Bachelor of Science in Biological Sciences from Stanford University.
Alvin Syh
CEO, Buchang Asset Management; General Manager, Anrich Capital Asia
Mr. Syh focuses on healthcare industry investments and managing assets of family offices, he is on the board of directors in a number of biotech companies. Mr. Syh is currently managing a number of well-known family offices, leading and implementing a full-spectrum of strategies in different sectors and stages, and cross regions, in U.S., EU, Israel and Asia. The global portfolio he worked on with success covers more than 80 investment funds and more than 280 direct investments portfolio companies.
Buchang Asset Management: Private investment arm of Buchang Pharma, a leading China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. Current market cap is $7.8 billion USD.
Karen Wong
Partner, Intellectual Property, WSGR
Dr. Karen Wong is a life sciences IP partner at Wilson Sonsini Goodrich & Rosati. Her practice includes freedom-to-operate and due-diligence studies, patent preparation and prosecution, opinion work, litigation strategy, and technology licensing. Karen serves as IP counsel to many venture-backed companies, and has worked on numerous major strategic alliance transactions, acquisitions, spin-outs, and IPOs.
Concentrating on cutting-edge biotechnology, Karen focuses her multidisciplinary practice on a combination of molecular biology, optical physics, chemical engineering, pharmacology, molecular diagnostics, and cellular physiology. She has developed technical expertise in DNA-sequencing techniques and instruments, antibody engineering and design, biofuels, drug delivery systems, gene therapies, cancer treatments, and point-of-care diagnostic tools.
Prior to practicing law, Karen conducted doctoral and postdoctoral research at Harvard and Tufts Medical School in molecular biology, cell biology, and physiology.
Karen is a co-founder and board member of BioE2E, which has built one of the largest communities of life sciences entrepreneurs in the Bay Area. A native of Sichuan, China, she is fluent in English, Mandarin, and Cantonese.
Jerry Xiao
CEO, Hermed Capital
Jerry is CEO of Hermed Capital, which is a VC fund focusing on the healthcare industry investment. He is Ph.D. in Pharmacology, member of Bio China Advisor Committee, finished his Postdoctoral training in Rochester University, during which he co-founded a pharmaceutical company with Dr. Paul Okunieff, and won STTR support from US government. He was BD head of Fosun Pharma, the deputy chief of the IPO team for Fosun Pharma Listing in Hong Kong Exchange, the vice general manager of Fosun Pharmaceutical Technological Center, in charge of the evaluation of new technology, R&D and investment, he reviewed more than 150 projects per annum.
He also served as a board member of Fochon Pharma (new drug development), Henlius (Biosimilar, antibody) and BeyondSpring (BYSI, Nasdaq), helping with the financing and technology transfer.
Grace Xu
SVP for Biomedicine Business, SanPower Denderon Corporation Chairman
As Dendreon Chairman, and Sanpower Group’s Senior Vice President, Ms Xu is responsible for setting corporate strategy for the Healthcare sector, and prioritizing future M&A focus. Ms. Xu has 25 years of experience in the Pharmaceutical and Biotech industry, has served a number of global leading companies, Novartis, AstraZeneca, and BMS. She has capabilities and experiences in general management, corporate strategy planning, business development, M&A, and new product planning. She also has extensive international experience, in US, Europe, Middle East and Asia.
Ms Xu has a MBA from Rotterdam school of management and a MS from University of Connecticut.
Jianbin Zhang
Partner, IDG Capital - Healthcare
Jiang Zhang
Managing Director, Ping An Venture
Jiang Zhang is the Managing Director of Ping An Ventures. His expertise covers several sectors including healthcare and fin-tech. He participated in developing innovation strategy for Ping An Ventures and executing strategic acquisitions.
Before Ping An Ventures, Jiang worked as Strategy Consultant in McKinsey & Company, where he is responsible for strategy consulting for healthcare and financial sector. He used to work for Philips Healthcare (Nederland),where he engaged in product development and marketing. He has accumulated rich experience in overseas.
Jiang obtained his MBA degree from INSEAD and Doctor of Computer Engineering from Eindhoven University of Technology.
Lily Zhang
Partner, CDH Venture
James Zhao
Founding Partner, LYFE Capital
James Zhao is a Founding Partner at LYFE Capital and focuses on investment in pharmaceutical, medical device, diagnostic, and animal health at our Shanghai offices. Prior to founding LYFE Capital, James was the first Managing Partner at Vivo Capital China and led many aspects of the formation of VIVO China. He has also worked as a consultant at the Monitor Group in Shanghai. His previous investments include Kanghui, Jingfeng (SZ: 0009008), Shanghai Hile (SHA: 603718.SS), Changchun Changsheng , NKF Pharm, SinoMedCare, Haier Biomedical etc.
James has over 19 years of experience with international engagements and Venture Capital /growth stage investment where he has a gained a wealth of knowledge in investment, operations, strategy, cross border business development, sales/marketing and executive placement.
Richard Zhao
GM Strategy and Investment & Sr. Vice President, Medical Device, Fosun Pharma
As Senior VP, Medical Device and GM of Strategy and Investment at Fosun Pharma, Mr. Richard Zhao holds an MBA degree from CEIBS and received executive education (CPD) from the Wharton School of University of Pennsylvania. He has about 20 years’ experience in M&A, Business Development and Sales & Marketing Management on both global and regional levels. Prior to joining Fosun Pharma, he held various executive positions at Bayer Healthcare and Philips Healthcare, driving international business growth and expansion. Richard has been one of early explorers in the 1990’s to introduce and help multinational companies enter and operate in China through Shanghai Free Trade Zone.
Fosun Pharma: Leading healthcare company in China. It engaged in the research and development, production and distribution of pharmaceuticals. Market size is around $10 billion.